Loading…
H.R. 7953119th CongressIn committeeLatest action Mar 17, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
The FAIR Act would let the FDA approve life-threatening disease drugs within 30 days if already approved in the EU, UK, or Canada.
45-second read · 4 questions answered below
The bill creates a fast-track FDA approval process for drugs treating life-threatening diseases that are already legally sold in the European Union, United Kingdom, or Canada. The FDA would have 30 days to decide, but could later withdraw approval if new safety evidence emerges or the foreign regulator withdraws its own approval. It also speeds up permission to start U.S. clinical trials using foreign authorization, with the same 30-day window.
This mainly affects patients with rare or life-threatening diseases seeking new treatments, and pharmaceutical and biotech companies developing those drugs. The FDA would also be affected, needing new review processes and a report to Congress after five years.
Relying on foreign regulatory decisions to speed up U.S. approvals raises questions about whether this affects the FDA's usual safety review standards.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the House Committee on Energy and Commerce.